{"id":"https://openalex.org/W2276941569","doi":"https://doi.org/10.18632/oncotarget.7446","title":"mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials","display_name":"mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials","publication_year":2016,"publication_date":"2016-02-17","ids":{"openalex":"https://openalex.org/W2276941569","doi":"https://doi.org/10.18632/oncotarget.7446","mag":"2276941569","pmid":"https://pubmed.ncbi.nlm.nih.gov/26895472","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5053632"},"language":"en","primary_location":{"id":"doi:10.18632/oncotarget.7446","doi":"https://doi.org/10.18632/oncotarget.7446","is_oa":true,"landing_page_url":"https://doi.org/10.18632/oncotarget.7446","pdf_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=7446&path%5B%5D=21455","source":{"id":"https://openalex.org/S126644158","display_name":"Oncotarget","issn_l":"1949-2553","issn":["1949-2553"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","medline","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316297","host_organization_name":"Impact Journals LLC","host_organization_lineage":["https://openalex.org/P4310316297"],"host_organization_lineage_names":["Impact Journals LLC"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=7446&path%5B%5D=21455","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110646634","display_name":"Maria Saveria Rotundo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I36443711","display_name":"Magna Graecia University","ror":"https://ror.org/0530bdk91","country_code":"IT","type":"education","lineage":["https://openalex.org/I36443711"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Maria Saveria Rotundo","raw_affiliation_strings":["Department of Experimental and Clinical Medicine, Medical Oncology, Magna Graecia University, Viale Europa, and Catanzaro, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Experimental and Clinical Medicine, Medical Oncology, Magna Graecia University, Viale Europa, and Catanzaro, Italy","institution_ids":["https://openalex.org/I36443711"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087222628","display_name":"Teresa Galeano","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I36443711","display_name":"Magna Graecia University","ror":"https://ror.org/0530bdk91","country_code":"IT","type":"education","lineage":["https://openalex.org/I36443711"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Teresa Galeano","raw_affiliation_strings":["Department of Experimental and Clinical Medicine, Medical Oncology, Magna Graecia University, Viale Europa, and Catanzaro, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Experimental and Clinical Medicine, Medical Oncology, Magna Graecia University, Viale Europa, and Catanzaro, Italy","institution_ids":["https://openalex.org/I36443711"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077467836","display_name":"Pierfrancesco Tassone","orcid":"https://orcid.org/0000-0002-8298-6787","observed_orcids":["https://orcid.org/0000-0002-8298-6787"]},"institutions":[{"id":"https://openalex.org/I36443711","display_name":"Magna Graecia University","ror":"https://ror.org/0530bdk91","country_code":"IT","type":"education","lineage":["https://openalex.org/I36443711"]},{"id":"https://openalex.org/I84392919","display_name":"Temple University","ror":"https://ror.org/00kx1jb78","country_code":"US","type":"education","lineage":["https://openalex.org/I84392919"]}],"countries":["IT","US"],"is_corresponding":false,"raw_author_name":"Pierfrancesco Tassone","raw_affiliation_strings":["Department of Experimental and Clinical Medicine, Translational Medical Oncology, Magna Graecia University, Viale Europa, Catanzaro, Italy","Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Experimental and Clinical Medicine, Translational Medical Oncology, Magna Graecia University, Viale Europa, Catanzaro, Italy","institution_ids":["https://openalex.org/I36443711"]},{"raw_affiliation_string":"Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia PA, USA","institution_ids":["https://openalex.org/I84392919"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101403092","display_name":"Pierosandro Tagliaferri","orcid":"https://orcid.org/0000-0003-3783-0895","observed_orcids":["https://orcid.org/0000-0003-3783-0895"]},"institutions":[{"id":"https://openalex.org/I36443711","display_name":"Magna Graecia University","ror":"https://ror.org/0530bdk91","country_code":"IT","type":"education","lineage":["https://openalex.org/I36443711"]}],"countries":["IT"],"is_corresponding":true,"raw_author_name":"Pierosandro Tagliaferri","raw_affiliation_strings":["Department of Experimental and Clinical Medicine, Medical Oncology, Magna Graecia University, Viale Europa, and Catanzaro, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Experimental and Clinical Medicine, Medical Oncology, Magna Graecia University, Viale Europa, and Catanzaro, Italy","institution_ids":["https://openalex.org/I36443711"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5101403092"],"corresponding_institution_ids":["https://openalex.org/I36443711"],"apc_list":null,"apc_paid":null,"fwci":0.2789,"has_fulltext":true,"cited_by_count":19,"citation_normalized_percentile":{"value":0.31273885,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"7","issue":"19","first_page":"27055","last_page":"27066"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9731000065803528,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9731000065803528,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.023600000888109207,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/her2-negative-breast-cancer","display_name":"HER2-negative breast cancer","score":0.9959999918937683},{"id":"https://openalex.org/keywords/hormone-therapy","display_name":"hormone therapy","score":0.8410000205039978},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8830000162124634},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9829999804496765},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.847000002861023},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.996999979019165},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9580000042915344},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.75}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.838044285774231},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.775422990322113},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.699303150177002},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6968327760696411},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6286946535110474},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.574905514717102},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.5492838621139526},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.44590723514556885},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4402170777320862},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.43682777881622314},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.427198588848114},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4227769076824188},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4164130389690399},{"id":"https://openalex.org/C29456083","wikidata":"https://www.wikidata.org/wiki/Q1221899","display_name":"Gynecology","level":1,"score":0.3437454104423523},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2221723198890686},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013629","descriptor_name":"Tamoxifen","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016016","descriptor_name":"Proportional Hazards Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017063","descriptor_name":"Outcome Assessment, Health Care","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D017063","descriptor_name":"Outcome Assessment, Health Care","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D018931","descriptor_name":"Antineoplastic Agents, Hormonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D020123","descriptor_name":"Sirolimus","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.18632/oncotarget.7446","doi":"https://doi.org/10.18632/oncotarget.7446","is_oa":true,"landing_page_url":"https://doi.org/10.18632/oncotarget.7446","pdf_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=7446&path%5B%5D=21455","source":{"id":"https://openalex.org/S126644158","display_name":"Oncotarget","issn_l":"1949-2553","issn":["1949-2553"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","medline","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316297","host_organization_name":"Impact Journals LLC","host_organization_lineage":["https://openalex.org/P4310316297"],"host_organization_lineage_names":["Impact Journals LLC"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5053632","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5053632","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"Text"},{"id":"pmid:26895472","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26895472","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.18632/oncotarget.7446","doi":"https://doi.org/10.18632/oncotarget.7446","is_oa":true,"landing_page_url":"https://doi.org/10.18632/oncotarget.7446","pdf_url":"http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=7446&path%5B%5D=21455","source":{"id":"https://openalex.org/S126644158","display_name":"Oncotarget","issn_l":"1949-2553","issn":["1949-2553"],"is_oa":true,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","medline","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310316297","host_organization_name":"Impact Journals LLC","host_organization_lineage":["https://openalex.org/P4310316297"],"host_organization_lineage_names":["Impact Journals LLC"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncotarget","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2276941569.pdf","grobid_xml":"https://content.openalex.org/works/W2276941569.grobid-xml"},"referenced_works_count":31,"referenced_works":["https://openalex.org/W246286872","https://openalex.org/W1908277068","https://openalex.org/W1965976637","https://openalex.org/W1988976358","https://openalex.org/W1990883066","https://openalex.org/W1991721331","https://openalex.org/W2002199578","https://openalex.org/W2031131661","https://openalex.org/W2044702943","https://openalex.org/W2078208862","https://openalex.org/W2079713876","https://openalex.org/W2097052490","https://openalex.org/W2097255042","https://openalex.org/W2100506877","https://openalex.org/W2109381544","https://openalex.org/W2113458582","https://openalex.org/W2127789666","https://openalex.org/W2131994307","https://openalex.org/W2135967493","https://openalex.org/W2151082560","https://openalex.org/W2153061474","https://openalex.org/W2153368125","https://openalex.org/W2156098321","https://openalex.org/W2167188058","https://openalex.org/W2169689529","https://openalex.org/W2243880667","https://openalex.org/W2259802687","https://openalex.org/W2346062491","https://openalex.org/W2600909081","https://openalex.org/W2991792334","https://openalex.org/W4294215472"],"related_works":["https://openalex.org/W2404398960","https://openalex.org/W4408957456","https://openalex.org/W2468594475","https://openalex.org/W2190912706","https://openalex.org/W3163533595","https://openalex.org/W4289878771","https://openalex.org/W2095838797","https://openalex.org/W4308060674","https://openalex.org/W2160120806","https://openalex.org/W2123290749"],"abstract_inverted_index":{"We":[0],"evaluated":[1],"if":[2],"standard":[3],"hormonal":[4],"therapy":[5,150],"(HT)":[6],"could":[7],"be":[8],"improved":[9],"by":[10],"the":[11,86,156],"addition":[12],"of":[13,16,53,85,117,141,151,158,168,171],"mammalian":[14],"target":[15],"rapamycin":[17],"inhibitors":[18],"(mTOR-I)":[19],"in":[20,51,83,115,138,146],"metastatic":[21,159],"luminal":[22,160],"breast":[23,161],"cancer.":[24],"A":[25],"meta-analysis":[26],"on":[27],"4":[28],"phase":[29],"II-III":[30],"randomized":[31],"clinical":[32],"trials":[33],"was":[34,49,63,81,94,113,125],"performed.":[35],"Pooled":[36,75,104],"hazard":[37],"ratio":[38,106],"(HR)":[39],"for":[40,66,77,108],"progression":[41,47],"free":[42],"survival":[43,79],"(PFS)/":[44],"time":[45],"to":[46],"(TTP)":[48],"0.62":[50],"favor":[52,84,116],"mTOR-I+HT":[54,147],"arm":[55,88,119],"(95%":[56,89,120],"confidence":[57],"interval":[58],"[CI]":[59],"0.55-0.70;":[60],"p<0.0001).":[61,123],"There":[62],"significant":[64,96,127],"heterogeneity":[65],"PFS/TTP":[67],"(Cochran's":[68,97,128],"Q":[69,98,129],"32,":[70],"p<0.0001,":[71],"I2":[72,101,132],"index":[73,102,133],"90.6%).":[74],"HR":[76],"overall":[78],"(OS)":[80],"0.84":[82],"combination":[87],"CI":[90,121],"0.71-0.99;":[91],"p=0.04).":[92],"Heterogeneity":[93,124],"not":[95,126],"4.47,":[99],"p=0.1,":[100],"55.3%).":[103],"risk":[105],"(RR)":[107],"objective":[109],"response":[110],"rate":[111],"(ORR)":[112],"0.88":[114],"experimental":[118],"0.85-0.91;":[122],"2.11,":[130],"p=0.3,":[131],"5.2%).":[134],"Adverse":[135],"events":[136],"(AEs),":[137],"particular":[139],"those":[140],"grade":[142],"3-4,":[143],"mostly":[144],"occurred":[145],"arm.":[148],"Combination":[149],"HT":[152],"plus":[153],"mTOR-I":[154],"improves":[155],"outcome":[157],"cancer":[162],"patients.":[163],"Our":[164],"results":[165],"provide":[166],"evidence":[167],"a":[169],"class-effect":[170],"these":[172],"targeting":[173],"molecules.":[174]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}